Ann: June 2017 Quarterly Report, page-3

Highlights:

- The Company closed the quarter with a cash position of $7.87 million.

- Manufacturing and distribution agreement with Knop Laboratories. The Company announced the execution of a strategic manufacturing and distribution agreement with Knop Laboratories. Knop Laboratories is a Chilean‐ based, independent pharmaceutical company with GMP manufacturing capability for Zelda’s cannabis medicines. Knop also operate a chain of pharmacies providing distribution capability once products are registered. (SA)

- The Company announced its clinical trial programme in Chile has expanded to include autism spectrum disorder (autism).

- The Company also reported that Zelda’s THC‐rich formulation had greater anti‐cancer effect than pure synthetic THC, across all cancer sub‐types including triple negative breast cancers.


Most we already knew, just need some confirmation on developments when each of these targets get hit. ZLD is one of the safer spec spaces currently imo. Some good pointers as we continue through the year, we are cashed up so continued trials should run without any worries about $.

DYOR. Best